Upstream production and R&D at non-AstraZeneca sites
Outsourced supply of API, F&P and transportation
Our sites and fleet
Site waste incineration and customer use
End-of-life for packaging and patient travel

Where our emissions occur
Upstream production and R&D at non-AstraZeneca sites
Outsourced supply of API, F&P and transportation
Our sites and fleet
Site waste incineration and customer use
End-of-life for packaging and patient travel

Percentage of total tCO₂e emissions*

Upstream: 61% (Scope 3)
Outsourced supply: 5% (Scope 3)
Our sites and fleet: 7% (Scopes 1 and 2)
Site waste incineration and customer use: 13% (Scope 3)
End-of-life for packaging and patient travel: 14% (Scope 3)

How we’re working to reduce GHG emissions

Working with suppliers including:
- Assessing data to understand the wider impact
- Identifying emissions hotspots through LCAs

Energy efficiencies including:
- Collaborating with peers on a supplier environmental data platform
- Switching from air to sea freight
- Enabling virtual conferencing

Investing in our sites and fleet including:
- Using 100% renewable power on all our sites by 2025
- Funding resource efficient capital projects

Product and process advancements including:
- Researching alternative propellants for pressurised metered dose inhaler therapies
- Investing in hazardous waste reduction

Product and packaging advancements including:
- Designing waste out of our packaging
- Enabling better adherence to reduce patient travel

Our total emissions: 6.6 million tCO₂e